Skip to main content
Novavax gets $ 1.6 billion for COVID-19 vaccine Vaccine production may begin at the end of 2020. Novavax has received $1.6 billion from the U.S. government to conduct trials and produce a potential vaccine for the disease-causing coronavirus COVID-19. It is planned that by January next year, Novavax will be able to produce and deliver 100 million doses of the new vaccine to consumers. Novavax received the largest cash grant from America's Department of Health and Human Services as part of the U.S. government's Operation Super Light Speed initiative, which aims to develop vaccines and therapies to combat COVID-19. As Stanley Erk, Novavax CEO, told Reuters - the US Department of Health has funded the production of 100 million doses of the vaccine, which is expected to be delivered in the fourth quarter of 2020 and can be completed by January-February next year. With funding from the federal government, the company will also be able to complete the third phase of the vaccin
Posts
Some US Hospitals Passing on Purchases of COVID Drug Some hospitals in the U.S. have been turning down part of their allocated supply of remdesivir, the COVID-19-fighting drug made by Gilead Sciences, the U.S. Health and Human Services Department confirmed Friday. From July 6 to September 8, state and territorial public health systems accepted about 72% of the remdesivir they were offered by HHS, a spokesperson confirmed Friday to Reuters. Hospitals then bought about two-thirds of what the states and territories accepted. The government has been leading the distribution of the drug, but that effort expires at the end of the month, and some hospitals are stockpiling remdesivir because they don’t know what the availability of the drug will be after September and want to be prepared if the pandemic flares this winter. Gilead did not respond to a request for comment from Reuters. Hospital say their supplies of the drug are adequate partly because they are only using it to treat the